PL3.5 Efficacy and safety of selinexor in recurrent glioblastoma

BACKGROUND: New treatment modalities are needed for recurrent glioblastoma (rGBM). Selinexor is a novel, oral selective inhibitor of nuclear export which forces nuclear retention of tumor suppressor proteins including p53 and p27, leading to apoptosis. We previously reported interim results showing...

詳細記述

保存先:
書誌詳細
出版年:Neuro Oncol
主要な著者: Lassman, A B, Wen, P Y, van den Bent, M, Plotkin, S R, Walenkamp, A, Green, A, Huang, X, Karla Rodriguez-Lopez, K, Kauffman, M G, Shacham, S, Mau-Soerensen, M
フォーマット: Artigo
言語:Inglês
出版事項: Oxford University Press 2019
主題:
Oral Presentations
オンライン･アクセス:https://ncbi.nlm.nih.gov/pmc/articles/PMC6794996/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/noz126.008
タグ: タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!

類似資料